Getinge (GETI) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
29 May, 2026Executive summary
Achieved strong organic net sales growth of 9.5% year-over-year in Q3 2025, with all business areas and regions contributing positively and order intake up 4.7%.
Recurring revenue products now account for 65% of sales, and high-margin products exceed two-thirds of total sales.
Financial position remains solid, supported by improved free cash flow and leverage well below internal thresholds.
Quality improvements led to a significant reduction in field actions relative to sales.
Strategic focus on increasing recurring revenue, high-margin product sales, and productivity improvements.
Financial highlights
Q3 2025 organic net sales up 9.5% year-over-year to SEK 8,226M; order intake up 4.7%.
Adjusted gross profit rose to SEK 4,051M (margin 49.2%), with gross margin up 0.9 percentage points; adjusted EBITA increased to SEK 1,079M (margin 13.1%).
Free cash flow improved to SEK 793M in Q3, supported by improved operating profits and working capital changes.
Net debt at quarter-end was SEK 11.1 billion, or SEK 8.6 billion adjusted for debt liabilities; leverage stood at 1.6x adjusted EBITDA, or 1.2x when adjusting for pension liabilities.
Tariff costs totaled SEK -108 million in Q3 and SEK -218 million year-to-date; currency effects negatively impacted adjusted gross profit by SEK -332M and EBITA by SEK -128M.
Outlook and guidance
Expect organic net sales growth of 2%-5% for 2025, maintaining long-term EPS growth target above 12%.
Anticipate a smoother second half of 2025, with balanced performance between Q3 and Q4.
Priorities include addressing quality in ACT, sustainability, productivity, cost control, and tariff mitigation.
Latest events from Getinge
- Organic growth, strong cash flow, and regulatory milestones achieved despite margin headwinds.GETI
Q1 202621 Apr 2026 - Full-year organic sales up 4.9% with resilient margins and strong outlook for 2026.GETI
Q4 202511 Apr 2026 - Strong sales and margin gains driven by Acute Care Therapies, with robust financial outlook.GETI
Q2 20243 Feb 2026 - Order intake up 10%, but margins and earnings pressured; 2024 growth outlook maintained.GETI
Q3 202419 Jan 2026 - Record sales and margin gains in Q4 2024, with strong outlook for 2025.GETI
Q4 20249 Jan 2026 - Double-digit sales and margin growth, low leverage, and a positive 2025 outlook despite uncertainties.GETI
Q1 202529 Nov 2025 - Organic growth and margins improved despite tariff and FX headwinds; outlook remains positive.GETI
Q2 202518 Jul 2025